Gastrointestinal Manifestations Among Patients With COVID19

NCT ID: NCT04544150

Last Updated: 2020-09-10

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

220 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-06-01

Study Completion Date

2020-09-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

many patients with confirmed infection with COVID-19 suffer from different symptoms and signs of gastrointestinal symptoms

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

many patients with COVID1-9 infection experienced many intestinal symptoms mainly abdominal pain, vomiting, and diarrhea. This study aimed to assess the frequency of GIT manifestations among patients with COVID-19 and its impact on the outcome

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Covid19

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* all patients with COVID19

Exclusion Criteria

* patient refusal to participate in the study
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Assiut University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Ahmed Mohammed Abu Elfatth

Al-rahji University Hospital, Faculty of Medicine, Assiut, Egypt

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Ahmed Abu elfatth

Role: PRINCIPAL_INVESTIGATOR

Assuit University Hospitals

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Ahmed

Al Minyā, Alminya, Egypt

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Egypt

References

Explore related publications, articles, or registry entries linked to this study.

Peck-Radosavljevic M, Danese S, Hartmann D, Saftoiu A, Van Hootegem P; UEG Public Affairs Committee. COVID-19 and digestive health. United European Gastroenterol J. 2020 Jun;8(5):624-626. doi: 10.1177/2050640620927955. No abstract available.

Reference Type BACKGROUND
PMID: 32450785 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

COVID19 and GUT

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

MSG and Gastrointestinal Motility
NCT01009658 COMPLETED NA
Relationship Between Diet and Gastritis
NCT07129824 NOT_YET_RECRUITING